CLGN
CollPlant Biotechnologies Ltd.
CLGN trails on the overall score without a compensating advantage in the available component scores.
NVO
Novo Nordisk A/S
NVO has the edge over CLGN overall, supported by stronger fundamentals.
CLGN Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
CLGN's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CLGN PE Valuation
CLGN has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
CLGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect CLGN's losses to shrink, with revenue declining.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CLGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$9.39 | +$1.91 |
| Q1 2026 | -$10.30 | +$1.90 |
| Q4 2025 | -$9.30 | +$5.30 |
| Q3 2025 | -$10.20 | +$5.10 |
| Q2 2025 | -$11.30 | +$4.00 |
| Q1 2025 | -$12.20 | -$5.50 |
| Q4 2024 | -$14.60 | -$8.10 |
| Q3 2024 | -$15.30 | -$9.20 |
CLGN is still losing money, but far less than before: $9.39 per share over the past year, against $21.40 at its worst in late 2019.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over CLGN on earnings quality, reporting a profit while its opponent remains loss making.
CLGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $108K | -40% |
| Q1 2026 | $73K | -96% |
| Q4 2025 | $60K | -63% |
| Q3 2025 | $77K | +1825% |
| Q2 2025 | $179K | -28% |
| Q1 2025 | $2.1M | +1997% |
| Q4 2024 | $164K | -45% |
| Q3 2024 | $4K | -91% |
CLGN's revenue has slid since its 2021 peak: $108,000 last quarter, down 40% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -2438% | -663 points |
| Q1 2026 | -4267% | -4187 points |
| Q4 2025 | -5250% | -2827 points |
| Q3 2025 | -4555% | +108995 points |
| Q2 2025 | -1775% | -5.9 points |
| Q1 2025 | -80% | +4337 points |
| Q4 2024 | -2423% | -728 points |
| Q3 2024 | -113550% | -102848 points |
CLGN's operating margin was −2438% last quarter, down 663 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over CLGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over CLGN on profitability, with a higher operating margin.
CLGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.5M | -$99K |
| Q1 2026 | -$3.1M | -$1.9M |
| Q4 2025 | -$3.2M | +$296.9K |
| Q3 2025 | -$2.9M | +$710K |
| Q2 2025 | -$2.4M | +$1.7M |
| Q1 2025 | -$1.2M | +$2.2M |
| Q4 2024 | -$3.5M | -$949K |
| Q3 2024 | -$3.6M | -155% |
CLGN has burned cash in almost every quarter: −$12M over the past year, against −$11M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over CLGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
CLGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.9% | +67.9K shares |
| 1 year | +22% | +259K shares |
| 3 years | +22% | +265K shares |
| 5 years | +41% | +423K shares |
| Available history | +209% | +976K shares |
CLGN has 1M diluted shares, up 22% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
CLGN hasn't bought back shares in the past year.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over CLGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CLGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2021 | -9.1x | Net Cash |
| Q3 2021 | -11.9x | Net Cash |
| Q2 2021 | -2.5x | Net Cash |
| Q1 2021 | -2.5x | Net Cash |
CLGN has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
CLGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.8 | Neutral |
| Stochastic | 23.1 | Neutral |
CLGN's weekly RSI is 50 (neutral) and its Stochastic is 23 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CLGN PE vs Healthcare Sector
CLGN has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CLGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.91 | 19% above |
| 20 week MA | $3.63 | 28% above |
| 50 week MA | $6.53 | 29% below |
| 100 week MA | $16.3 | 72% below |
| 200 week MA | $39.0 | 88% below |
CLGN has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
CLGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58.0 | $100.5 | +73% |
| 2021 | $100.5 | $132.2 | +32% |
| 2022 | $132.2 | $83.4 | -37% |
| 2023 | $83.4 | $63.9 | -23% |
| 2024 | $63.9 | $35.7 | -44% |
| 2025 | $35.7 | $15.3 | -57% |
| 2026 YTD | $15.3 | $4.64 | -70% |
CLGN has finished four years in a row lower, and it's down 70% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over CLGN on returns for 2026, with the stronger performance.